PillRx only · Capsule, Coated, Extended Release · Oral
Tacrolimus Extended-Release Capsules
Brands: Astagraf Xl · Tacrolimus · Tacrolimus
2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US6 NDCs
2 active makers
2 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$12.070
Latest avg · Jan 14, 2026
-21%
Since Jan 13, 2025
2
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
1.3K
Rx · 2026 Q1
96K
Units dispensed
-5%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it2 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Chengdu Suncadia Medicine Co., Ltd. | unknown | 3 | SUPPLYING |
| Astellas Pharma US, Inc. | unknown | 3 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Dec 23, 2024RECALLRecall (Class I): Astagraf XL (tacrolimus extended-release capsules) 0.5 mg, 30-count bottles, RX Only, Product of Japan, Distributed by:…
Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules — Recalling firm: Astellas Pharma US Inc. — Nationwide in the USA